ATXS
Price
$5.59
Change
+$0.15 (+2.76%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
316.03M
45 days until earnings call
COGT
Price
$7.11
Change
-$0.22 (-3.00%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
808.95M
46 days until earnings call
Interact to see
Advertisement

ATXS vs COGT

Header iconATXS vs COGT Comparison
Open Charts ATXS vs COGTBanner chart's image
Astria Therapeutics
Price$5.59
Change+$0.15 (+2.76%)
Volume$8.81K
Capitalization316.03M
Cogent Biosciences
Price$7.11
Change-$0.22 (-3.00%)
Volume$95.78K
Capitalization808.95M
ATXS vs COGT Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. COGT commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and COGT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (ATXS: $5.60 vs. COGT: $7.11)
Brand notoriety: ATXS and COGT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 171% vs. COGT: 276%
Market capitalization -- ATXS: $316.03M vs. COGT: $808.95M
ATXS [@Biotechnology] is valued at $316.03M. COGT’s [@Biotechnology] market capitalization is $808.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileCOGT’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • COGT’s FA Score: 0 green, 5 red.
According to our system of comparison, ATXS is a better buy in the long-term than COGT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while COGT’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 5 bearish.
  • COGT’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ATXS and COGT are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -4.44% price change this week, while COGT (@Biotechnology) price change was -1.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

COGT is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COGT($809M) has a higher market cap than ATXS($316M). COGT YTD gains are higher at: -8.910 vs. ATXS (-37.360). ATXS has higher annual earnings (EBITDA): -124.4M vs. COGT (-284.04M). ATXS has more cash in the bank: 295M vs. COGT (246M). ATXS has less debt than COGT: ATXS (5.06M) vs COGT (17.1M). ATXS (0) and COGT (0) have equivalent revenues.
ATXSCOGTATXS / COGT
Capitalization316M809M39%
EBITDA-124.4M-284.04M44%
Gain YTD-37.360-8.910419%
P/E RatioN/AN/A-
Revenue00-
Total Cash295M246M120%
Total Debt5.06M17.1M30%
FUNDAMENTALS RATINGS
ATXS vs COGT: Fundamental Ratings
ATXS
COGT
OUTLOOK RATING
1..100
7372
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
4941
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (58) in the Biotechnology industry is in the same range as COGT (81) in the Miscellaneous industry. This means that ATXS’s stock grew similarly to COGT’s over the last 12 months.

COGT's Profit vs Risk Rating (68) in the Miscellaneous industry is in the same range as ATXS (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as COGT (99) in the Miscellaneous industry. This means that ATXS’s stock grew similarly to COGT’s over the last 12 months.

COGT's Price Growth Rating (41) in the Miscellaneous industry is in the same range as ATXS (49) in the Biotechnology industry. This means that COGT’s stock grew similarly to ATXS’s over the last 12 months.

COGT's P/E Growth Rating (100) in the Miscellaneous industry is in the same range as ATXS (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSCOGT
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EDIAX11.24N/A
N/A
Eaton Vance Global Income Builder A
PRCGX23.52N/A
N/A
Perritt MicroCap Opportunities Investor
PRNHX52.65N/A
N/A
T. Rowe Price New Horizons
MIOPX31.91N/A
N/A
Morgan Stanley Inst International Opp A
JIJIX15.05N/A
N/A
JHancock International Dynamic Gr I

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+2.94%
XENE - ATXS
53%
Loosely correlated
+0.65%
COGT - ATXS
53%
Loosely correlated
-3.07%
CRNX - ATXS
53%
Loosely correlated
-1.22%
ERAS - ATXS
53%
Loosely correlated
+1.98%
TRDA - ATXS
51%
Loosely correlated
-1.57%
More

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
-3.07%
SPHDF - COGT
63%
Loosely correlated
N/A
IDYA - COGT
55%
Loosely correlated
-4.04%
XNCR - COGT
55%
Loosely correlated
-3.10%
ATXS - COGT
52%
Loosely correlated
+2.94%
CGON - COGT
52%
Loosely correlated
-0.46%
More